NCT01331291View on ClinicalTrials.gov

Bosutinib in Adult Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Glioblastoma
Interventions
DRUG

bosutinib

Taken orally

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana=Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01331291 - Bosutinib in Adult Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter